Betting on the Underdogs..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Awesome Info. Thanks for the effort and work..
That was nice. I hope for a huge bounce today.. Have a good one!!
Here we goooooo!! UPUPUP..
MTVX-Looking good to go with Merger, and production.. HUGE BUYING OPPORTUNITY. PROVE IT, just did..
TPAC-Looks a little shady. What is the motivation for buying here?
I am thinking the same. I just keep waiting to see those huge green BUY blocks. There is nice interest here. Have a good one..
Well ya gotta go with your gut. Good luck to ya, in other stocks of chance..
OK FDBL-up with youre PPS or off with their heads!!. (feelin piraty).. Have a great evening/morn everyone..
OK FDBL-up with youre PPS or off with their heads!!. (feelin piraty).. Have a great evening/morn everyone..
FDBL-Ouch Man.. Please bounce. OK then, have a nice evening all..
FDBL-AWESOME PETE! Looking for a large rise in PPS..
Great board! MU on watch for a bottom bounce. Financials are trending down yoy, hoping for groundbreaking news. Have a great day everyone..
MTVX-So good to see ya again!! Have a great day
MTVX-Technology Elevated READY for primetime. news is close. The rest is made up stories..
HEY PETE.. Another 15 foot chart needed: INO.. Thanks Bud..
Thank you Pete!! Have a great weekend!!
TY Gold.. Have a great weekend..
INO-Here's Why Wall Street Is Buzzing About Inovio Pharmaceuticals Once Again
Inovio's experimental Zika virus vaccine is turning heads, but shareholders would be wise to keep their eyes on something more important.
What: Shares of Inovio Pharmaceuticals (NASDAQ:INO), a clinical-stage biotech company focused on developing DNA-based vaccines to treat cancer and other infectious diseases, surged as much as 12% during Tuesday's trading session before finishing higher by 11.1%. Look no further than the hype surrounding the Zika virus, the virus being spread by mosquitos throughout South and Central America, as the root cause for Inovio's gains.
So what: According to newly published research in the journal Nature from Beth Israel Deaconess Medical Center, Walter Reed Army Institute of Research, and Harvard University, two experimental vaccines designed to fight the Zika virus were 100% effective in protecting against the Zika virus strain in mice. One vaccine was a purified inactivated virus, but the other was a DNA-based vaccine.
This second portion is particularly notable, since Inovio and GeneOne Life Science are developing a DNA-based Zika vaccine based on a strain of genetically engineered cells derived from the Brazilian Zika strain. As a refresher, Inovio received clearance earlier this month to move forward on early stage clinical testing in humans, and H.C. Wainwright earlier today reaffirmed in a note that clinical testing is expected to begin soon.
No vaccine currently exists to treat the Zika virus, and more than 1 million cases alone have been reported in Brazil. While the effects of the Zika virus can seem like a really bad case of the flu, causing fever and joint pain, the disease has also been linked with a rise of microcephaly in newborns and Guilain-Barre syndrome in adults.
Now what: Inovio has been one of the few biotechnology bright spots in 2016, with its shares up 37% year to date. However, I would caution investors not to get too caught up in Zika hysteria. While I could be all wet, and a Zika virus vaccine could prove quite profitable for Inovio and GeneOne, more often than not pandemic potential diseases are quashed by the cooperation of global medical agencies. Also, Inovio's vaccine would require large and regular purchases from government agencies in order to be profitable, which may be far from a guarantee. I'd suggest that Inovio's year-to-date gains are already more than reflective of what a Zika vaccine could do for Inovio's top and bottom line.
Instead, I'd encourage investors to really pay close attention to Inovio's developing line of cancer immunotherapies. Inovio's most advanced immunotherapy is VGX-3100, a potential treatment for cervical dysplasia that delivered a statistically significant improvement over the placebo in terms of disease regression and human papillomavirus types 16 and 18 clearance in midstage studies. Because Inovio's development platform is DNA-based, success for VGX-3100 could spell promise for the remainder of its immunotherapy pipeline.
INO-Here's Why Wall Street Is Buzzing About Inovio Pharmaceuticals Once Again
Inovio's experimental Zika virus vaccine is turning heads, but shareholders would be wise to keep their eyes on something more important.
What: Shares of Inovio Pharmaceuticals (NASDAQ:INO), a clinical-stage biotech company focused on developing DNA-based vaccines to treat cancer and other infectious diseases, surged as much as 12% during Tuesday's trading session before finishing higher by 11.1%. Look no further than the hype surrounding the Zika virus, the virus being spread by mosquitos throughout South and Central America, as the root cause for Inovio's gains.
So what: According to newly published research in the journal Nature from Beth Israel Deaconess Medical Center, Walter Reed Army Institute of Research, and Harvard University, two experimental vaccines designed to fight the Zika virus were 100% effective in protecting against the Zika virus strain in mice. One vaccine was a purified inactivated virus, but the other was a DNA-based vaccine.
This second portion is particularly notable, since Inovio and GeneOne Life Science are developing a DNA-based Zika vaccine based on a strain of genetically engineered cells derived from the Brazilian Zika strain. As a refresher, Inovio received clearance earlier this month to move forward on early stage clinical testing in humans, and H.C. Wainwright earlier today reaffirmed in a note that clinical testing is expected to begin soon.
No vaccine currently exists to treat the Zika virus, and more than 1 million cases alone have been reported in Brazil. While the effects of the Zika virus can seem like a really bad case of the flu, causing fever and joint pain, the disease has also been linked with a rise of microcephaly in newborns and Guilain-Barre syndrome in adults.
Now what: Inovio has been one of the few biotechnology bright spots in 2016, with its shares up 37% year to date. However, I would caution investors not to get too caught up in Zika hysteria. While I could be all wet, and a Zika virus vaccine could prove quite profitable for Inovio and GeneOne, more often than not pandemic potential diseases are quashed by the cooperation of global medical agencies. Also, Inovio's vaccine would require large and regular purchases from government agencies in order to be profitable, which may be far from a guarantee. I'd suggest that Inovio's year-to-date gains are already more than reflective of what a Zika vaccine could do for Inovio's top and bottom line.
Instead, I'd encourage investors to really pay close attention to Inovio's developing line of cancer immunotherapies. Inovio's most advanced immunotherapy is VGX-3100, a potential treatment for cervical dysplasia that delivered a statistically significant improvement over the placebo in terms of disease regression and human papillomavirus types 16 and 18 clearance in midstage studies. Because Inovio's development platform is DNA-based, success for VGX-3100 could spell promise for the remainder of its immunotherapy pipeline.
Agreed. Good to see ya round..
Yep-It's a sticky wicket at this point.. GLTY, and have a great weekend there in the states..
Lies- Those numbers are not even close..
Very incorrcet. Read and learn how this scam is run. In a basement on chestnut street..
BullShit Email. The photoshop HTML is all embedded.
Folks-You will be glad you are holding shares tomorrow, I can feel a surge in volume and price tomorrow!!
LoL--Color blind to GREEN only... Win a few lose even more, is my story.. Have a great day!!
$INO-HUGE gains coming. Zika Virus elimination and cancer projects.. WINNER!!
$TVIX-Gonna blow today!!
Man o man this should take off!!
DJ Analyst Estimates for U.S. Earnings Thursday
Last update: 30/06/2016 2:55:00 am
Standard & Poor's 500 stock index companies scheduled to report quarterly earnings Thursday, with per-share earnings estimates provided by FactSet Research Systems Inc.:
Company Symbol Quarter Mean Report Time
Micron Tech Inc. (MU) 3Q (.10) 12:00 AM
(At least three brokerage analysts must be forecasting EPS for the company to be included in this report. The Factset EPS estimate is the mean. Estimates can reflect GAAP or non-GAAP numbers.)
(END) Dow Jones Newswires
June 30, 2016 05:55 ET (09:55 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
$GEVO-Moving up Pre Market Load em up..
$GEVO-Moving up Pre Market Nice numbers!! And they will get your g6 to emit rainbows and Unicorns!!
$GEVO-Moving up Pre Market Nice numbers!!
$MTVX-NEWS is close. Dealer Expos and purchases. Merger will work well..
Thanks!! LoL.. Have a great day, I think I will throw down another 5k. Wow, what a slot machine GEVO has been. I hope they can outlast, outprofit the Competition.. GLTA
Right on fellow human. THAT was an awesome post. I am in my 50's and with your permission, I would like to add "bad enough to shrivel the nuts on a brass bongo monkey" to my rep-itar(sp), may I ? Good luck to you and everyone. Good evening!!
SPAM-peddling his "Money Making Program" Bullshit.
That is a horrible chart. Proves IT IS OVER
$GEVO-Ready for launch..
OK GEVO time to run with the big dogs.. Let's break through dollar land. Enough of this timid trading..
$MTVX - Ready for merger news.. BUYING..